Clinical trial
Patient-reported Tolerability and Loco-regional Control After Proton Therapy in Patients With Recurrent or Second Primary Head and Neck Cancer Eligible for Re-irradiation, a Multicentre Phase II Single Arm Trial
NCT07922967 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Patient-reported Tolerability and Loco-regional Control After Proton Therapy in Patients With Recurrent or Second Primary Head and Neck Cancer Eligible for Re-irradiation, a Multicentre Phase II Single Arm Trial
- Lead sponsor
- Oslo University Hospital
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- November 20, 2026
- Completion date
- June 20, 2045
- Enrollment
- 60 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
head & neck cancer
Arms
As registered; 1 arm.
-
Recurrance/second primay disease of HNC
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Tolerability -patient-reported dysphagia measured with EORTC QLQ-HN43 dysphagia scale
Change in patient-reported dysphagia measured with the EORTC QLQ-HN43 dysphagia scale group level mean score
Lead sponsor's other trials
Oslo University Hospital, most recent start first.
+828 more trials See the organization page
Similar trials
Same condition (Head and Neck Neoplasms) and phase, most recent start first.
+514 more trials See the condition page